Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion for Amgen last year and now Mylan will be hoping its F...
Original Article: Amgen faces first Neulasta biosimilar rival as FDA approves Mylan drug